BioCryst Pharmaceuticals (BCRX) announced that it has dosed the first subject in its two-part Phase 2 clinical trial, APeX-1, assessing next-generation killikrein inhibitor BCX7353 for the treatment of hereditary angioedema (HAE). The study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353 in ~50 HAE patients. Part 1 will randomize subjects 1:1 to receive either a once-daily oral dose of 350 mg of BCX7353 or placebo for four weeks. Part 2 will characterize the dose responses in 14 additional patients who will be randomized to receive either 250 mg or 125 mg of BCX7353 once daily or placebo.